Description

Vyvgart Efgartigimod Alfa is an engineered Fc fragment that binds with high affinity to FcRn, preventing IgG recycling and thereby accelerating IgG degradation. This results in a marked and sustained reduction in total IgG, including pathogenic autoantibodies. Clinically approved for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy in China, this formulation serves as a powerful tool in research settings for modeling IgG?mediated autoimmune conditions, exploring FcRn pharmacology, and developing antibody clearance interventions. Each vial contains 400?mg efgartigimod alfa in a buffered injectable solution. Strictly for laboratory research use only.

Product Specifications

Mechanism of Action & Research Applications

Vyvgart functions as a neonatal Fc receptor blocker: it competes with endogenous IgG for FcRn binding, preventing IgG recycling and promoting lysosomal degradation. This targeted reduction in IgG—including autoantibodies—makes it an excellent model for studying FcRn biology, autoantibody-associated conditions such as myasthenia gravis or CIDP, and therapeutic antibody removal kinetics. It has broad utility in immunology, neurology, and immunotherapy research.

Side Effects (For Reference Only in Research Models)

In clinical and analogous model observations, potential effects include mild respiratory infections, headaches, urinary tract infections, paresthesia (tingling/numbness), and occasional infusion site discomfort. These are typically transient. Monitor inflammatory markers and immune cell profiles during experimental protocols.

Disclaimer

Vyvgart Efgartigimod Alfa Injection is strictly intended for laboratory research use only. Not for human or veterinary therapeutic or diagnostic application.